CL2018003407A1 - Anticuerdos anti-pd-1, método para producir el mismo y método para usar el mismo. - Google Patents

Anticuerdos anti-pd-1, método para producir el mismo y método para usar el mismo.

Info

Publication number
CL2018003407A1
CL2018003407A1 CL2018003407A CL2018003407A CL2018003407A1 CL 2018003407 A1 CL2018003407 A1 CL 2018003407A1 CL 2018003407 A CL2018003407 A CL 2018003407A CL 2018003407 A CL2018003407 A CL 2018003407A CL 2018003407 A1 CL2018003407 A1 CL 2018003407A1
Authority
CL
Chile
Prior art keywords
antibodies
same
produce
oncology
refers
Prior art date
Application number
CL2018003407A
Other languages
English (en)
Inventor
Dmitry Valentinovich Morozov
Andrei Borisovich Ulitin
Iakov Iurevich Ustiugov
Roman Alekseevich Ivanov
Viktoriia Mikhailovna Ekimova
Yulia Sergeevna Chernykh
Timofey Aleksandrovich Nemankin
Valery Vladimirovich Solovyev
Anna Konstantinovna Vladimirova
Irina Andreevna Bulankina
Sergei Vasilyevich Diduk
Olga Vladimirovna Goncharova
Anna Vladimirovna Eroshova
Marina Vladimirovna Artiukhova
Dmitry Valeryevich Korzhavin
Original Assignee
Biocad Joint Stock Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocad Joint Stock Co filed Critical Biocad Joint Stock Co
Publication of CL2018003407A1 publication Critical patent/CL2018003407A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A LA BIOTECNOLOGÍA Y COMPRENDE ANTICUERPOS MONOCLONALES AISLADOS, EN PARTICULAR ANTICUERPOS MONOCLONALES HUMANOS, QUE SE UNEN ESPECÍFICAMENTE A PD-1 CON ALTA AFINIDAD. LOS ANTICUERPOS DE ACUERDO CON LA INVENCIÓN PUEDEN SER ANTICUERPOS QUIMÉRICOS, HUMANIZADOS O HUMANOS, O FRAGMENTOS DE UNIÓN A ANTÍGENO DE LOS MISMOS, Y PUEDEN USARSE COMO UN AGENTE MEDICINAL EN ONCOLOGÍA E INMUNO-ONCOLOGÍA, PARA TRATAR ENFERMEDADES RELACIONADAS CON DIVERSOS TRASTORNOS DE LA PROLIFERACIÓN Y DESARROLLO CELULAR. LA INVENCIÓN TAMBIÉN SE REFIERE A MÉTODOS PARA PRODUCIR LOS ANTICUERPOS INDICADOS, Y A UN MÉTODO PARA TRATAR ENFERMEDADES HUMANAS USANDO DICHOS ANTICUERPOS.
CL2018003407A 2016-07-13 2018-11-29 Anticuerdos anti-pd-1, método para producir el mismo y método para usar el mismo. CL2018003407A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2016128487A RU2656181C1 (ru) 2016-07-13 2016-07-13 Анти-pd-1-антитела, способ их получения и способ применения

Publications (1)

Publication Number Publication Date
CL2018003407A1 true CL2018003407A1 (es) 2019-03-29

Family

ID=60953256

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018003407A CL2018003407A1 (es) 2016-07-13 2018-11-29 Anticuerdos anti-pd-1, método para producir el mismo y método para usar el mismo.

Country Status (21)

Country Link
US (1) US11136408B2 (es)
EP (1) EP3486257A4 (es)
JP (1) JP6993992B2 (es)
KR (1) KR102482710B1 (es)
CN (1) CN110023335B (es)
BR (1) BR112019000436A2 (es)
CA (1) CA3021372A1 (es)
CL (1) CL2018003407A1 (es)
CO (1) CO2019001246A2 (es)
CR (1) CR20190009A (es)
EC (1) ECSP19010852A (es)
JO (1) JOP20190002A1 (es)
MA (1) MA44547B1 (es)
MX (1) MX2018014937A (es)
NI (1) NI201900002A (es)
NZ (1) NZ750221A (es)
PE (1) PE20190450A1 (es)
PH (1) PH12018550179A1 (es)
RU (1) RU2656181C1 (es)
WO (1) WO2018013017A1 (es)
ZA (1) ZA201900792B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3132021C (en) 2015-11-18 2024-03-12 Merck Sharp & Dohme Corp. Pd1 and/or lag3 binders
CN110291109B (zh) 2017-01-20 2023-01-31 大有华夏生物医药集团有限公司 人程序性死亡受体pd-1的单克隆抗体及其片段
KR102808275B1 (ko) 2017-04-14 2025-05-20 탈락 테라퓨틱스, 인크. 면역조절 폴리뉴클레오티드, 이의 항체 접합체, 및 이의 사용 방법
CR20190550A (es) 2017-06-05 2020-04-05 Janssen Biotech Inc Anticuerpos que se unen específicamente a pd-1 y métodos de uso
TWI901940B (zh) 2017-08-03 2025-10-21 美商安進公司 介白素-21突變蛋白及治療方法
JP2019122373A (ja) 2018-01-12 2019-07-25 アムジエン・インコーポレーテツド 抗ｐｄ−１抗体及び治療方法
WO2019148410A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1 antibodies
CN112424231B (zh) * 2018-07-19 2022-09-13 大有华夏生物医药集团有限公司 抗pd-1抗体及其剂量和用途
CN109652453B (zh) * 2018-12-29 2021-04-06 杭州科兴生物科技有限公司 一种基于pd-1/pdl-1阻断功能及生物效应的抗癌药物快速筛选方法
WO2020239558A1 (en) 2019-05-24 2020-12-03 Pfizer Inc. Combination therapies using cdk inhibitors
JP7680967B2 (ja) * 2019-06-14 2025-05-21 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｐｄ－１に対する抗体およびその使用方法
CN111420049A (zh) 2019-08-22 2020-07-17 Biocad股份公司 抗-pd1抗体prolgolimab的水性药物组合物及其应用
RU2753282C2 (ru) * 2019-09-19 2021-08-12 Закрытое Акционерное Общество "Биокад" ИММУНОЦИТОКИН, ВКЛЮЧАЮЩИЙ ГЕТЕРОДИМЕРНЫЙ БЕЛКОВЫЙ КОМПЛЕКС НА ОСНОВЕ IL-15/IL-15Rα, И ЕГО ПРИМЕНЕНИЕ
US11920136B2 (en) 2020-02-28 2024-03-05 Tallac Therapeutics, Inc. Transglutaminase-mediated conjugation
MA59827B1 (fr) 2020-05-26 2024-10-31 Boehringer Ingelheim International Gmbh Anticorps anti-pd-1
WO2022118197A1 (en) 2020-12-02 2022-06-09 Pfizer Inc. Time to resolution of axitinib-related adverse events
JP2023553157A (ja) * 2020-12-10 2023-12-20 ユーティレックス カンパニー リミテッド 抗－ｐｄ－１抗体およびその用途
MX2023011663A (es) 2021-03-31 2023-10-11 Merus Nv Dominios de union a pd-1 novedosos.
CN117500493A (zh) 2021-04-08 2024-02-02 拜奥卡德联合股份公司 使用pd-1抗体组合治疗恶性瘤
WO2023057882A1 (en) 2021-10-05 2023-04-13 Pfizer Inc. Combinations of azalactam compounds with a pd-1 axis binding antagonist for the treatment of cancer
WO2023079428A1 (en) 2021-11-03 2023-05-11 Pfizer Inc. Combination therapies using tlr7/8 agonist
CN116925223A (zh) * 2022-04-02 2023-10-24 普米斯生物技术(珠海)有限公司 抗pd-1单克隆抗体及其衍生物和用途
US20260098092A1 (en) * 2022-10-05 2026-04-09 Chulalongkorn University Monoclonal antibodies against human programmed cell death protein 1 (pd-1)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2161336T5 (pl) * 2005-05-09 2017-10-31 Ono Pharmaceutical Co Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
KR101586617B1 (ko) * 2007-06-18 2016-01-20 머크 샤프 앤 도메 비.브이. 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체
US8062852B2 (en) * 2007-10-01 2011-11-22 The Children's Hospital And Regional Medical Center Detection and treatment of autoimmune disorders
NO2504364T3 (es) * 2009-11-24 2018-01-06
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
EP2545078A1 (en) 2010-03-11 2013-01-16 UCB Pharma, S.A. Pd-1 antibody
ES2692268T5 (en) * 2011-03-29 2025-02-26 Roche Glycart Ag Antibody fc variants
JP6742903B2 (ja) * 2013-05-02 2020-08-19 アナプティスバイオ インコーポレイティッド プログラム死−１（ｐｄ−１）に対する抗体
LT3702373T (lt) * 2013-09-13 2022-11-10 Beigene Switzerland Gmbh Anti-pd1 antikūnai ir jų naudojimas terapijai ir diagnostikai
PL3177640T3 (pl) * 2014-08-08 2020-11-02 The Board Of Trustees Of The Leland Stanford Junior University Charakteryzujące się wysokim powinowactwem środki terapeutyczne naśladujące PD-11 i sposoby ich wykorzystania
GB201419084D0 (en) 2014-10-27 2014-12-10 Agency Science Tech & Res Anti-PD-1 antibodies
TWI595006B (zh) * 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法

Also Published As

Publication number Publication date
NI201900002A (es) 2019-06-11
AU2017297138A8 (en) 2019-02-28
ZA201900792B (en) 2020-03-25
AU2017297138A2 (en) 2019-02-21
NZ750221A (en) 2022-09-30
JP6993992B2 (ja) 2022-01-14
CN110023335A (zh) 2019-07-16
MA44547B1 (fr) 2021-09-30
CO2019001246A2 (es) 2019-02-19
EP3486257A1 (en) 2019-05-22
CA3021372A1 (en) 2018-01-18
RU2656181C1 (ru) 2018-05-31
KR102482710B1 (ko) 2023-01-02
JOP20190002A1 (ar) 2019-01-10
PH12018550179A1 (en) 2019-03-11
JP2019527543A (ja) 2019-10-03
AU2017297138A1 (en) 2019-02-14
ECSP19010852A (es) 2019-06-30
PE20190450A1 (es) 2019-03-29
BR112019000436A2 (pt) 2019-10-01
EP3486257A4 (en) 2020-03-04
CR20190009A (es) 2019-06-05
MA44547A1 (fr) 2020-01-31
WO2018013017A1 (ru) 2018-01-18
MX2018014937A (es) 2019-05-16
US20190127478A1 (en) 2019-05-02
US11136408B2 (en) 2021-10-05
CN110023335B (zh) 2024-05-17
KR20190029641A (ko) 2019-03-20

Similar Documents

Publication Publication Date Title
ECSP19010852A (es) Anticuerpos anti-pd-1, un método de producción y un método para su uso
CL2020001974A1 (es) Anticuerpos anti-trem2 y métodos para utilizarlos. (divisional solicitud 201903093)
CY1123977T1 (el) Anti-pd-1 και anti-lag3 αντισωματα για την θεραπεια του καρκινου
MX2020012286A (es) Metodos para tratar canceres y potenciar la eficacia de agentes terapeuticos para el redireccionamiento de celulas t.
CL2020003071A1 (es) Proteínas de unión multiespecíficas y mejoras con estas
CL2019001926A1 (es) Anticuerpos anti-tigit y fragmentos de unión a antígeno; composición farmacéutica que los comprende; polinenucleótido que codifica dicho anticuerpo; vector que los comprende, célula hospedera; método para producir dicho anticuerpo o fragmento de unión a antígeno del mismo; y uso en el tratamiento del cáncer. (divisional de solicitud 310-2017).
BR112016020752A2 (pt) ?anticorpo isolado ou fragmento de ligação a antígeno do mesmo, composição farmacêutica, e, métodos para tratamento de um câncer ou tumor expressando egfrviii e para tratamento de um câncer, redução de crescimento de tumor e/ou causação de regressão de tumor em um paciente?
CO2018005932A2 (es) Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas
ECSP18096095A (es) Anticuerpos a la alfa-sinucleína y usos de los mismos
CL2018003758A1 (es) Conjugados anticuerpo anti-dll3-fármaco y métodos de uso. (divisional solicitud 201800458)
MX2019006072A (es) Metodos para tratamiento de cancer que comprenden agentes de enlace al inmunoreceptor de celulas t con dominios ige itim (tigit).
CL2018002490A1 (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123. (divisional solicitud 201701866)
AR115389A1 (es) Anticuerpo antagonista de cd73
AR110875A1 (es) Anticuerpo humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y agente para tratar o prevenir trastornos cognitivos mediante su uso
MX2018010473A (es) Terapia de combinacion con anticuerpos anti cumulo de diferenciacion 73 (cd73).
BR112017006468A2 (pt) anticorpo biespecífico, composição farmacêutica, kit, uso de uma combinação de um anticorpo biespecífico e método de tratamento de câncer
BR112016010513A2 (pt) anticorpos anti-il-17, método de produção e uso dos mesmos
MX2022001896A (es) Formulaciones anti-c5 de alta concentracion.
MX2016008472A (es) Anticuero monoclonal neutralizador de anti-il-33-humana.
MX2018013520A (es) Anticuerpos monoclonales de adn dirigidos a moléculas de punto de control.
CO2019005101A2 (es) Anticuerpo biespecífico heterodimérico estructural de anticuerpo natural anti-pd-1/anti-her2 y método para preparar el mismo
MX2021002299A (es) Anticuerpos de anti-cd33 y metodos para usarlos.
EA201992460A1 (ru) Антитела-агонисты btla и их применение
MX2020008730A (es) Regímenes de dosificación de anticuerpo b7-h4.
MX2018013484A (es) Nuevos anticuerpos anti-tnfrsf21 y modos de uso.